Cited by 755Malaria Research and ControlBacterial Infections and VaccinesTravel-related health issues

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Open access

The RTS,S Clinical Trials Partnership·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1208394PMC PMC10915853

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial. METHODS: We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 6 to 12 weeks of age at the time of the first vaccination in conjunction with Expanded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. Vaccine efficacy against the first or only episode of clinical malaria during the 12 months after vaccination, a coprimary end point, was analyzed with the use of Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy against severe malaria, safety, and immunogenicity were also assessed. RESULTS: The incidence of the first or only episode of clinical malaria in the intention-to-treat population during the 14 months after the first dose of vaccine was 0.31 per person-year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a vaccine efficacy of 30.1% (95% confidence interval [CI], 23.6 to 36.1). Vaccine efficacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine efficacy against severe malaria was 26.0% (95% CI, -7.4 to 48.6) in the intention-to-treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. Serious adverse events occurred with a similar frequency in the two study groups. One month after administration of the third dose of RTS,S/AS01, 99.7% of children were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 209 EU per milliliter (95% CI, 197 to 222). CONCLUSIONS: The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1208394

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Self-citation
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants
Siegrist, C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00342-6 · Cited by 350
Design and Analysis of Vaccine Studies
Halloran, M. E., Longini, I. M., & Struchiner, C. J. (2009) · Statistics for biology and health · doi:10.1007/978-0-387-68636-3 · Cited by 332
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
Aponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Glycoconjugate vaccines and immune interference: A review
Dagan, R., POOLMAN, J. T., & Siegrist, C. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.026 · Cited by 270
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
Abdulla, S., Oberholzer, R., Juma, O. A., Kubhoja, S. D., Machera, F., Membi, C. D., Omari, S., Urassa, A., Mshinda, H., Jumanne, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807773 · Cited by 239

Flagged first, then by citations

Show all 31 references

1 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Brabin B, 1990, Trop Dis Bull, 87, R1

Sorted by citations

Items 501–600 of 755

Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35
Kalra, A., Edula, J. R., Gupta, P. K., Pandey, A. K., & Chauhan, V. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165720 · Cited by 8
Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
Vandoolaeghe, P., & Schuerman, L. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.30.142.13152 · Cited by 11
The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission
Bartsch, S. M., Stokes-Cawley, O. J., Buekens, P. M., Asti, L., Bottazzi, M. E., Strych, U., Wedlock, P. T., Mitgang, E. A., Meymandi, S., Falcón‐Lezama, J. A., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.078 · Cited by 8
Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP)
Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.934676 · Cited by 8
Two decades of malaria control in Malawi: Geostatistical Analysis of the changing malaria prevalence from 2000-2022
Mategula, D., Gichuki, J., Chipeta, M. G., Chirombo, J., Kalonde, P. K., Gumbo, A., Kayange, M., Samuel, V., Kwizombe, C., Hamuza, G., et al. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.19390.2 · Cited by 14
Full maturation of in vitro Plasmodium falciparum oocysts using the AlgiMatrix 3D culture system
Zhou, Y., Hatzakis, K., MacMillen, Z., Laohajaratsang, M., Grieser, A. M., Itsara, L. S., Do, J., Davie, J. W., Ghosh, A. K., & Avril, M. (2024) · Malaria Journal · doi:10.1186/s12936-024-05079-7 · Cited by 11
Fun with maths: exploring implications of mathematical models for malaria eradication
Eckhoff, P. A., Bever, C. A., Gerardin, J., & Wenger, E. A. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-486 · Cited by 7
Development and application of a high-throughput screening assay for identification of small molecule inhibitors of the P. falciparum reticulocyte binding-like homologue 5 protein
Sleebs, B. E., Jarman, K. E., Frölich, S., Wong, W., Healer, J., Dai, W., Lucet, I. S., Wilson, D. W., & Cowman, A. F. (2020) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2020.10.008 · Cited by 7
CD8+ Trms against malaria liver-stage: prospects and challenges
Zhu, C., Jiao, S., & Xu, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344941 · Cited by 8
Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease
Wang, N., & Wang, T. (2024) · Biotechnology Journal · doi:10.1002/biot.202300658 · Cited by 11
Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection
Spreng, R. L., Seaton, K. E., Lin, L., Hilliard, S., Horn, G. Q., Abraha, M., Deal, A. W., Li, K., Carnacchi, A. J., Feeney, E., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.178801 · Cited by 9
The effect of disease transmission on time-aggregated treatment efficacy estimates: a critical analysis of factors influencing the RTS,S and R21 malaria vaccine phase 3 trials
Macià, D., Pons-Salort, M., Moncunill, G., & Dobaño, C. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00090-8 · Cited by 11
Permethrin-Treated Baby Wraps for the Prevention of Malaria
Boyce, R. M., Shook‐Sa, B. E., Ndizeye, R., Baguma, E., Giandomenico, D., Cassidy, C. A., Eshun, S., Siedner, M. J., Staedke, S. G., Ntaro, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501628 · Cited by 7
A whole‐killed, blood‐stage lysate vaccine protects against the malaria liver stage
Lu, X., Liu, T., Zhu, F., Chen, L., & Xu, W. (2016) · Parasite Immunology · doi:10.1111/pim.12386 · Cited by 7
Mother-Newborn Pairs in Malawi Have Similar Antibody Repertoires to Diverse Malaria Antigens
Boudová, S., Walldorf, J. A., Bailey, J. A., Divala, T. H., Mungwira, R. G., Mawindo, P., Pablo, J. V., Jasinskas, A., Nakajima, R., Ouattara, A., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00136-17 · Cited by 8
Pasteur Approach to a Malaria Vaccine May Take the Lead
Good, M. F. (2013) · Science · doi:10.1126/science.1244157 · Cited by 7
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
Garrett, N., Dintwe, O., Monaco, C. L., Jones, M., Seaton, K. E., Church, E. C., Grunenberg, N. A., Hütter, J., deCamp, A. C., Huang, Y., et al. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003438 · Cited by 6
The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network
Neeland, M. R., Shi, W., Collignon, C., Meeusen, E. N. T., Didierlaurent, A. M., & de Veer, M. J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13088 · Cited by 5
Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from Plasmodium Infection in a Murine Model
Reeder, S. M., Bah, M. A., Tursi, N. J., Brooks, R. C., Patel, A. R., Esquivel, R. N., Eaton, A., Jhun, H., Chu, J. D., Kim, K., et al. (2021) · Infection and Immunity · doi:10.1128/iai.00728-20 · Cited by 7
Plasmodium
Liu, T., Zhu, F., Tan, N., Chen, S., & Xu, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00012-5 · Cited by 6
MalarImDB: an open-access literature-based malaria immunology database
Deroost, K., Opdenakker, G., & den Steen, P. E. V. (2014) · Trends in Parasitology · doi:10.1016/j.pt.2014.04.006 · Cited by 6
Advancement Towards an Approved Vaccine to Target Plasmodium Falciparum Malaria
Taylor-Robinson, A. W. (2014) · International Journal of Immunology · doi:10.11648/j.iji.20140205.11 · Cited by 6
Heat Shock Proteins as Targets for Novel Antimalarial Drug Discovery
Daniyan, M. O. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-78397-6_9 · Cited by 6
Transient Expression of Plasmodium berghei MSP8 and HAP2 in the Marine Protozoan Parasite Perkinsus marinus
Cold, E. R., Vasta, G. R., & Robledo, J. A. F. (2016) · Journal of Parasitology · doi:10.1645/16-88 · Cited by 7
Yeast lysates carrying the nucleoprotein from measles virus vaccine as a novel subunit vaccine platform to deliver Plasmodium circumsporozoite antigen
Jacob, D., Ruffié, C., Combredet, C., Formaglio, P., Amino, R., Ménard, R., Tangy, F., & Sala, M. (2017) · Malaria Journal · doi:10.1186/s12936-017-1908-7 · Cited by 6
A probabilistic model of pre-erythrocytic malaria vaccine combination in mice
Atcheson, E., Bauza, K., & Reyes‐Sandoval, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209028 · Cited by 6
Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial
Valéa, I., Adjei, S., Usuf, E. A., Traoré, O., Ansong, D., Tinto, H., Boateng, H. O., Somé, M. A., Buabeng, P. B. Y., Vekemans, J., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1695457 · Cited by 6
Malaria Control
Tediosi, F., Lengeler, C., Castro, M. C., Shretta, R., Levin, C., Wells, T. N. C., & Tanner, M. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0524-0_ch13 · Cited by 6
Better Drug Therapy for the Children of Africa: Current Impediments to Success and Potential Strategies for Improvement
MacLeod, S. M., Finch, J. K., Macharia, W., & Anabwani, G. M. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0015-7 · Cited by 6
Malaria vaccine gives disappointing results
Butler, D. (2012) · Nature · doi:10.1038/nature.2012.11785 · Cited by 6
Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?
Wilson, C. B., & Karp, C. L. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0152 · Cited by 5
Screening of novel malaria DNA vaccine candidates using full-length cDNA library
Shibui, A., Nakae, S., Watanabe, J., Sato, Y., Tolba, M. E. M., Doi, J., Shiibashi, T., NOGAMI, S., Sugano, S., & Hozumi, N. (2013) · Experimental Parasitology · doi:10.1016/j.exppara.2013.09.007 · Cited by 5
Respiratory Syncytial Virus Protein Structure, Function and Implications for Subunit Vaccine Development
McCarthy, M., Villafana, T. L., Stillman, E. A., & Esser, M. T. (2014) · Future Virology · doi:10.2217/fvl.14.60 · Cited by 5
Heterogeneity in disease risk induces falling vaccine protection with rising disease incidence
Margheri, A., Rebelo, C., & Gomes, M. G. M. (2016) · Dynamical Systems · doi:10.1080/14689367.2016.1187115 · Cited by 8
Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy
Scalsky, R. J., Dwivedi, A., Stabler, T. C., Mbambo, G., Ouattara, A., Lyke, K. E., Takala‐Harrison, S., & da Silva, J. C. F. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126783 · Cited by 5
NIAID meeting report: Improving malaria vaccine strategies through the application of immunological principles
Mo, A. X. Y., & Augustine, A. D. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.09.011 · Cited by 6
Whole-Sporozoite Malaria Vaccines
Mendes, A. M., Scholzen, A., Mueller, A., Khan, S. M., Sauerwein, R. W., & Prudêncio, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-45210-4_6 · Cited by 5
Biomedical Applications of Viral Nanoparticles in Vaccine Therapy
Venkataraman, S., Reddy, V. S., & Khurana, S. M. P. (2020) · Springer eBooks · doi:10.1007/978-981-32-9898-9_9 · Cited by 5
Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination
Parzych, E. M., Miura, K., Long, C. A., & Burns, J. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232355 · Cited by 5
Plasmodium falciparum-Specific Memory B-Cell and Antibody Responses Are Associated With Immunity in Children Living in an Endemic Area of Kenya
Jahnmatz, P., Nyabundi, D., Sundling, C., Widman, L., Mwacharo, J. K., Musyoki, J., Otieno, E. G., Ahlborg, N., Bejon, P., Ndungu, F. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.799306 · Cited by 5
Genomic signature of early T-cell response is associated with lower antibody titer threshold for sterilizing immunity
Ong, E. Z., Gan, E. S., de Alwis, R., Wijaya, L., Ong, X. M., Zhang, M., Wong, A. W. L., Cheung, Y. B., Zellweger, R. M., Ooi, E. E., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.03.013 · Cited by 5
Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model
Reeder, S. M., Reuschel, E. L., Bah, M. A., Yun, K., Tursi, N. J., Kim, K. Y., Chu, J. D., Zaidi, F. I., Yilmaz, I., Hart, R. J., et al. (2020) · Vaccines · doi:10.3390/vaccines8010021 · Cited by 6
Hematology and blood serum chemistry reference intervals for children in Iganga district of Uganda
Kironde, F., Sekikubo, M., Naiwumbwe, H., Namusoke, F., Buwembo, W., Kiwuwa, S. M., Okech, B. A., Noor, R. A., Chilengi, R., Mworozi, E. A., et al. (2013) · Health · doi:10.4236/health.2013.58171 · Cited by 5
Circumsporozoite protein as a potential target for antimalarials
Fernández-Arias, C., Mashoof, S., Huang, J., & Tsuji, M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1058709 · Cited by 5
Malaria vaccine development: over 40 years of trials and tribulations
Corradin, G., & Engers, H. D. (2014) · doi:10.2217/fmeb2013.13.233 · Cited by 5
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorphaPreprint
Wetzel, D., Chan, J.-A., Suckow, M., Barbian, A., Weniger, M., Jenzelewski, V., Reiling, L., Richards, J. S., Anderson, D. A., Kouskousis, B. P., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/595538 · Cited by 5
Protozoan Diseases: Malaria Clinical Features, Management, and Prevention
Showler, A., Kain, K. C., & Boggild, A. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00360-x · Cited by 5
Discovery of 1,3,4-oxadiazoles with slow-action activity against Plasmodium falciparum malaria parasites
Andrews, K. T., Fisher, G. M., Firmin, M., Liepa, A. J., Wilson, T., Gardiner, J., Mohri, Y., Debele, E. A., Rai, A., Davey, A. K., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116796 · Cited by 4
Varying Immunizations With Plasmodium Radiation-Attenuated Sporozoites Alter Tissue-Specific CD8+ T Cell Dynamics
Frank, R., Gabel, M., Heiss, K., Mueller, A., & Graw, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01137 · Cited by 5
Plasmodium yoelii Infection Enhances the Expansion of Myeloid-Derived Suppressor Cells via JAK/STAT3 Pathway
Zhu, Y., Zhou, L., Mo, L., Hong, C., Pan, L., Lin, J., Qi, Y., Tan, S., Qian, M., Hu, T., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300541 · Cited by 4
Extensive genetic diversity in Plasmodium vivax from Sudan and its genetic relationships with other geographical isolates
Albsheer, M. M. A., Hubbard, A., Dieng, C. C., Gebremeskel, E. I., Ahmed, S., Rougeron, V., Ibrahim, M. E., Lo, E., & Hamid, M. M. A. (2024) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2024.105643 · Cited by 4
Recent Trends in Malaria Vaccine Research Globally: A Bibliometric Analysis From 2005 to 2022
Chutiyami, M. (2024) · Journal of Parasitology Research · doi:10.1155/2024/8201097 · Cited by 4
In silico improvement of affinity for highly protective anti-malarial antibodies
Reveiz, M., Tripathi, P., Pereira, L. D. S., Kiyuka, P. K., Liu, T. W. B., Yang, Y., Zhang, B., Benmohamed, D., Bonilla, B. G., Carruthers, C. W., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112903 · Cited by 4
Development of drugs for severe malaria in children
Cheah, P. Y., Parker, M. J., & Dondorp, A. M. (2016) · International Health · doi:10.1093/inthealth/ihw038 · Cited by 4
Malaria Vaccine Development: Recent Advances alongside the Barriers
Nega, D., Alemu, A., & Tasew, G. (2016) · Journal of Bacteriology & Parasitology · doi:10.4172/2155-9597.1000300 · Cited by 4
Travel to Tropical Countries: A Review of Travel-Related Infectious Diseases
Rapose, A. (2013) · Tropical Medicine & Surgery · doi:10.4172/2329-9088.1000128 · Cited by 4
Sieve Analysis Using the Number of Infecting Pathogens
Follmann, D. A., & Huang, C. (2017) · Biometrics · doi:10.1111/biom.12833 · Cited by 4
Epidemiological Determinants of Successful Vaccine Development
Nishiura, H., & Mizumoto, K. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5689 · Cited by 4
Development and Assessment of Transgenic Rodent Parasites for the Preclinical Evaluation of Malaria Vaccines
Espinosa, D. A., Radtke, A. J., & Zavala, F. P. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_33 · Cited by 5
A Prime/Boost PfCS14KM/MVA-sPfCSMVaccination Protocol Generates Robust CD8+T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria
Vijayan, A., Mejías‐Pérez, E., Espinosa, D. A., Raman, S. C., Sorzano, C. Ó. S., Zavala, F. P., & Estéban, M. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00494-16 · Cited by 4
Assessing trends in vaccine efficacy by pathogen genetic distance.
Benkeser, D. C., Juraska, M., & Gilbert, P. B. (2020) · PubMed · Cited by 4
Monoclonal Antibodies
Klein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 4
Protozoan Diseases: Malaria, Clinical Features, Management and Prevention
Showler, A., Kazmi, K., Obetta, C., Igboanugo, S., & Boggild, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00108-3 · Cited by 4
Role of malaria exposure and off-target responses on RTS,S/AS02A vaccine immunogenicity and protection in Mozambican children
Fuentes, E., Jairoce, C., Macià, D., Mayer, L., Torres-Yaguana, J. P., Vidal, M., Santano, R., Narum, D. L., Cavanagh, D. R., Gamain, B., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01167-0 · Cited by 3
A 3D culture model facilitates mass production of in vitro Plasmodium falciparum haemolymph-like sporozoites
Hatzakis, K., MacMillen, Z., Kirtley, P., Aleshnick, M., Martinson, T., Gupta, P., Swearingen, K. E., Wilder, B. K., Davie, J. W., & Avril, M. (2025) · Malaria Journal · doi:10.1186/s12936-025-05471-x · Cited by 3
Analysis of the immune response of a new malaria vaccine based on the modification of cryptic epitopes
Shen, Y., Wang, J., Huang, Y., Liang, J., Liu, X., Wu, D., Jiang, H., Zhao, Y., & Li, Y. (2016) · Parasitology Research · doi:10.1007/s00436-016-4931-7 · Cited by 4
Adaptive Immunity to Plasmodium Blood Stages
Wykes, M., Stephens, R., & Cockburn, I. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-45210-4_3 · Cited by 3
Inclusion of non-target antigen in vaccination favors generation of OVA specific CD4 memory T cells
Mohankrishnan, A., Patel, H., Bhurani, V., Parmar, R., Yadav, N., Dave, N., Rana, S., Gupta, S., Madariya, J., Vyas, P., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.11.005 · Cited by 3
Immunomic Identification of Malaria Antigens Associated With Protection in Mice
Siau, A., Huang, X., Loh, H. P., Zhang, N., Meng, W., Sze, S. K., Rénia, L., & Preiser, P. R. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000997 · Cited by 3
Quantification of Vaccine Waning as a Challenge Effect
Janvin, M., & Stensrud, M. J. (2024) · Journal of the American Statistical Association · doi:10.1080/01621459.2024.2408776 · Cited by 6
Effect of RTS,S/AS01E vaccine booster dose on cellular immune responses in African infants and children
Mitchell, R. A., Macià, D., Jairoce, C., Mpina, M., Naidu, A., Chopo-Pizarro, A., Vázquez-Santiago, M., Campo, J. J., Aíde, P., Aguilar, R., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00977-y · Cited by 3
Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein
Parra, M., Liu, X., Derrick, S. C., Yang, A., Molina-Cruz, A., Barillas-Mury, C. V., Zheng, H., Pham, P. T., Sedegah, M., Belmonte, A. D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141141 · Cited by 3
Malaria
Dondorp, A. M., & von Seidlein, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00117-9 · Cited by 3
The Quest for Affordable Artemisinin
Cook, S. P. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.1 · Cited by 3
The RTS,S/AS01 vaccine continues to show modest protection against malaria in African infants and children
Rosenthal, P. J. (2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2015-110231 · Cited by 3
Decrease in circulating CD25 hi Foxp3 + regulatory T cells following vaccination with the candidate malaria vaccine RTS,S
Parsons, E. L., Epstein, J. E., Sedegah, M., Villasante, E. F., & Stewart, A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.07.008 · Cited by 3
Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
Kaguthi, G., Nduba, V., Rabuogi, P., Okelloh, D. A., Ouma, S. G., Blatner, G. L., Gelderbloem, S., Mitchell, E. M. H., Scott, C. P., Verver, S., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-09051-3 · Cited by 3
Immunogenicity, Efficacy, and Safety of a Novel Synthetic Microparticle Pre-Erythrocytic Malaria Vaccine in Multiple Host Species
Powell, T., Tang, J. T., Mitchell, R., DeRome, M., Jacobs, A., Palath, N., Cardenas, E., Yorke, M., Boyd, J., Kaba, S. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11121789 · Cited by 2
Efficacy and immunogenicity of RTS,S/AS01 and R21/Matrix-M malaria vaccines: - Systematic review and meta-analysis
Asjad, H., Sadiq, M. W., Siddiqui, S., Sherali, S., Yousafzai, M. T., Taseen, S., & Qamar, F. N. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103222 · Cited by 3
Major Global Vaccine Challenges: Recent Progress in Malaria Vaccine Development
Vekemans, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00019-9 · Cited by 2
Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development
Roman, F. P., Coccia, M., & Schuerman, L. (2020) · Malaria Journal · doi:10.1186/s12936-020-03334-1 · Cited by 2
Molecular characterization of Plasmodium falciparum DNA-3-methyladenine glycosylase
Pinthong, N., Limudomporn, P., Vasuvat, J., Adisakwattana, P., Rattaprasert, P., & Chavalitshewinkoon-Petmitr, P. (2020) · Malaria Journal · doi:10.1186/s12936-020-03355-w · Cited by 2
Causal inference methods for vaccine sieve analysis with effect modification
Yang, G., Balzer, L. B., & Benkeser, D. C. (2022) · Statistics in Medicine · doi:10.1002/sim.9302 · Cited by 2
Virus-like particle vaccines
Mukhopadhyay, E. S., Hill, A. V. S., & Salman, A. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91146-7.00007-x · Cited by 2
Transdermal Transmission Blocking Vaccine for Malaria using a Solid-in-Oil Dispersion
Tanaka, K., Minamihata, K., Wakabayashi, R., Lee, J. M., Miyata, T., Kusakabe, T., Kamiya, N., & Goto, M. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.10.031 · Cited by 2
Experimental vaccination by single dose sporozoite injection of blood-stage attenuated malaria parasites
Sattler, J. M., Keiber, L., Abdelrahim, A. G., Zheng, X., Jäcklin, M., Zechel, L., Moreau, C., Steinbrück, S., Fischer, M. D., Janse, C. J., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00101-6 · Cited by 2
The long road for vaccine development with difficulties and hopes
Ge, Q., Chen, P., Cheng, Y., & Xiao, Y. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2396886 · Cited by 2
Serological markers for enhanced malaria surveillance from an elimination point of view: A narrative review
Mamnani, V., Verma, K., Bharti, P. K., & Nitika, N. (2025) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/apjtm.apjtm_84_24 · Cited by 2
Distinct evolutionary regimes across domains of the Plasmodium falciparum CSP gene
Al-Kaisy, R., Bhatt, S., & Duchêne, D. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-98456-4 · Cited by 2
Genetic diversity in the Plasmodium falciparum next-generation blood stage vaccine candidate antigen PfCyRPA in Senegal
Ba, A., Thiam, L. G., Pouye, M. N., Guo, Y., Patel, S. D., Sene, S. D., Diallo, F., Li, R., Cisse, A., Guerra, N., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-36257-z · Cited by 1
Uso de modelos de primatas neotropicais para pesquisa em malária: um histórico dos 25 anos de colaboração entre o Laboratório de Pesquisa em Malária (IOC, Fiocruz) e o Centro Nacional de Primatas (IEC, SVS)
Pratt-Riccio, L. R., Riccio, E. K. P., Bianco‐Júnior, C., Alves, F. A., Baptista, B. D. O., Totino, P. R. R., Muniz, J. A. P. C., de Castro, P. H. G., Carvalho, L. J. M., & Daniel‐Ribeiro, C. T. (2021) · Revista Pan-Amazônica de Saúde · doi:10.5123/s2176-6223202100462 · Cited by 2
Economic Analyses of Vaccine Policies
Miller, M. A., & Gessner, B. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00078-x · Cited by 2
Progress toward vaccines for cholera, dengue, malaria, and Ebola
Cunningham, K. C., & Hayney, M. S. (2014) · Journal of the American Pharmacists Association · doi:10.1331/japha.2014.14541 · Cited by 2
Malaria in Children - Prevention and Management
Dramowski, A., Frigati, L. J., Rabie, H., & Cotton, M. F. (2014) · Infectious Disorders - Drug Targets · doi:10.2174/1871526513666131129154446 · Cited by 2
Malaria Diagnosis, Therapy, Vaccines, and Vector Control
Basilico, N., Spaccapelo, R., & D’Alessandro, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-09432-8_2 · Cited by 2
RTS,S/AS01 malaria vaccine (Mosquirix™): a guide to its use
Keating, G. M. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0290-9 · Cited by 2
Implications from predicted B-cell and T-cell epitopes of Plasmodium falciparum merozoite proteins EBA175-RII and Rh5
Wamae, K., KEMRI-Wellcome Trust Collaborative Programme, K., Ochola‐Oyier, L. I., & KEMRI-Wellcome Trust Collaborative Programme, K. (2016) · Bioinformation · doi:10.6026/97320630012082 · Cited by 2
Malaria Vaccines
Ballou, W. R., & Vekemans, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00035-3 · Cited by 2
Public-private collaboration to advance the development and benefit-risk assessment of vaccines: The Innovative Medicines Initiative
Wittelsberger, A. (2013) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2013.4.2 · Cited by 2
The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age
Bartsch, S. M., Asti, L., Stokes-Cawley, O. J., Sim, S. Y., Bottazzi, M. E., Hotez, P. J., & Lee, B. Y. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.10.023 · Cited by 2

Authors: The RTS, S. C. T. P.
Affiliations: Program for Appropriate Technology in Health (US)
Corresponding author: The RTS,S Clinical Trials Partnership
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-12-13
Volume: 367
Issue: 24
Pages: 2284-2295
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1208394
PMC: PMC10915853
OpenAlex: W2244674613
Cited by: 752
References: 31
Citations by year: 2026: 18 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 36 · 2021: 42 · 2020: 45 · 2019: 47 · 2018: 40 · 2017: 58 · 2016: 67 · 2015: 74 · 2014: 111 · 2013: 103 · 2012: 7
FWCI: 91.09
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion, other-oa)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
IHI Repository (acceptedVersion)
PubMed Central (acceptedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders: Bill and Melinda Gates Foundation
GlaxoSmithKline
Wellcome Trust (092654)
National Institutes of Health (CC999999)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords: RTS,S/AS01, malaria vaccine, infants, vaccine efficacy, clinical malaria, severe malaria, circumsporozoite protein, co-administration, immunogenicity, vaccine safety, Plasmodium falciparum, African infants, malaria prevention, vaccine adverse events
MeSH terms: Africa, Female, Humans, Immunization Schedule, Infant, Male, Plasmodium falciparum, Vaccines, Synthetic, Incidence, Proportional Hazards Models, Malaria, Falciparum, Treatment Outcome, Malaria Vaccines, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks